CORC

在结果中检索

CORC

浏览/检索结果: 共207条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review 期刊论文
TRANSLATIONAL CANCER RESEARCH, 2022
作者:  He, Libin;  Shen, Xiabo;  Liu, Yiyuan;  Gao, Lu;  Wu, Jiayi
收藏  |  浏览/下载：17/0  |  提交时间：2022/12/23
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer 期刊论文
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 卷号: 14
作者:  Yan, Min;  Yuan, Peng;  Ouyang, Quchang;  Cheng, Ying;  Han, Guohui
收藏  |  浏览/下载：23/0  |  提交时间：2022/12/23
Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China 期刊论文
THORACIC CANCER, 2022
作者:  Xu, Chunwei;  Si, Lu;  Wang, Wenxian;  Li, Ziming;  Song, Zhengbo
收藏  |  浏览/下载：28/0  |  提交时间：2022/12/22
The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer 期刊论文
TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 卷号: 21
作者:  Chen, Keyu;  Wu, Jiayi;  Fang, Ziru;  Shao, Xiying;  Wang, Xiaojia
收藏  |  浏览/下载：21/0  |  提交时间：2022/12/22
Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis 期刊论文
ANNALS OF PALLIATIVE MEDICINE, 2022, 卷号: 11
作者:  Lei, Lei;  Chen, Rucheng;  Fan, Lei;  Zheng, Weijun;  Wang, Xiaojia
收藏  |  浏览/下载：15/0  |  提交时间：2022/12/23
Identified potential pathogenic variants of BARD1 in 1449 Chinese high-risk breast cancer patients. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Wang, Rong;  Ye, Weiwu;  Chen, Zhanhong;  Shao, Xiying;  Cao, Wenming
收藏  |  浏览/下载：4/0  |  提交时间：2022/12/23
Apatinib combined with chemotherapy versus single chemotherapy in HER-2 negative advanced breast cancer: A randomized, controlled, open-label phase II study. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Chen, Zhanhong;  Wang, Xiaojia;  Huang, Jian;  Zheng, Yabing;  Shao, Xiying
收藏  |  浏览/下载：12/0  |  提交时间：2022/12/23
Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Shen, Xia-Bo;  Wu, Jia-Yi;  Chen, Ke-Yu;  Fang, Zi-Ru;  Li, Guang-Liang
收藏  |  浏览/下载：10/0  |  提交时间：2022/12/23
The population characteristic analysis in RecurIndex for clinical decision-making on adjuvant therapy for early breast cancer: Results of a real-world study. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Wang, Xiaojia;  Lei, Lei;  Fu, Peifen;  Wang, Ouchen;  Xie, Xiaohong
收藏  |  浏览/下载：12/0  |  提交时间：2022/12/23
Platelet-to-Lymphocyte ratio (PLR) as a predictive marker in HER2 positive metastatic breast cancer patients treated with first-line trastuzumab therapy. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Fang, Zi-Ru;  Shen, Xia-Bo;  Wu, Jia-Yi;  Chen, Ke-Yu;  Shao, Xi-Ying
收藏  |  浏览/下载：8/0  |  提交时间：2022/12/23

©版权所有 ©2017 CSpace - Powered by CSpace